CA
NZ
UK
AU
IND
US
Basel Medical Group (NASDAQ:BMGL) was indicated down 8.06% in the October 9, 2026 premarket session on the screener, on a listed price of USD 3.60 and premarketVolumeof 12,507 shares. The listed price is the October 8 close, when the shares rose about 9.76% from …
bioAffinity Technologies (NASDAQ:BIAF) was indicated down 5.85% in the October 9, 2026 premarket session on the screener, on a listed price of USD 5.64 and premarketVolumeof 13,667 shares. The screener tags an other event. A published headline list shows that on October 8 the …
DataMEDS AI (NASDAQ:MEDS) was indicated down 5.29% in the October 9, 2026 premarket session on the screener, on a listed price of USD 3.40 and premarketVolumeof 17,377 shares. The listed price is the October 8 close, when the shares rose USD 0.52, or 18.06%. …
Nexalin Technology (NASDAQ:NXL) was indicated down 5.11% in the October 9, 2026 premarket session on the screener, on a listed price of USD 4.11 and premarket volume of 580 shares. The screener lists no catalyst and a search found no company release or filing …
Veradermics (NYSE:MANE) shares rose roughly 14% to 16% on October 8, 2026, to between USD 126.63 and USD 128.85, according to market data in the topics file. No company news, filing or analyst note that explains the rise was identified. The file lists the …
China SXT Pharmaceuticals (NASDAQ:SXTC) fell about 88% on October 8, 2026 after announcing a registered direct offering at USD 1.50 per share. The topics file lists it as the top loser of the day and classes the offering terms as reported from a release …
Solid Biosciences (NASDAQ:SLDB) was indicated up 5.72% in the October 9, 2026 premarket session on the screener, on a listed price of USD 6.82 and premarket volume of 1,482 shares. The screener lists no catalyst, and a search found no company announcement or filing …
Haemonetics (NYSE:HAE) shares closed at USD 119.47 on October 8, 2026, up 17.46%, which implies a prior close near USD 101.71, simple arithmetic on the two published figures. A recap attributed the move to an updated non-exclusive US supply agreement with CSL Plasma covering …
Kyverna Therapeutics (NASDAQ:KYTX) was indicated up 5.34% in the October 9, 2026 premarket session on the screener, on a listed price of USD 6.18 and premarket volume of only 100 shares. The screener tags the catalyst as news, yet a search found no company …
The FDA approved Tecentriq, known generically as atezolizumab, on October 8, 2026 for adjuvant treatment of stage III colon cancer with deficient mismatch repair, abbreviated dMMR. Adjuvant means given after surgery to reduce the chance of recurrence. The approval came one day before the …
Please wait processing your request...